horizon
Horizon and Fulcrum Therapeutics form CRISPR collaboration
September 6, 2016Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases
Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform …
Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug
May 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights
Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …
Depomed criticised by investors and urged to explore potential sale
April 11, 2016Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value
Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …
Horizon receives European go-ahead for Ravicti
December 2, 2015Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders
The European Commission has approved Ravicti for rare urea cycle disorders. Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
Takeover hostilities resume between Depomed and Horizon
August 10, 2015Sales and Marketing Depomed, horizon, hostile bid, nucynta, takeover, tapentadol
The bitter takeover row between Horizon and Depomed has escalated after Depomed dismissed its suitor’s latest advances, and warned it …
Depomed rejects Horizon’s latest takeover bid
July 30, 2015Sales and Marketing Depomed, horizon, mergers and acquisitions, takeovers
Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company. The Irish pharma company …
Horizon attempts a hostile $3bn Depomed takeover
July 9, 2015Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover
Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …
AZ and Horizon in cancer tie-up
January 8, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, horizon, medimunne
AstraZeneca has signed a deal with British biotech firm Horizon Discovery to look at a number of genotypes to see …
AstraZeneca sells arthritis drug for $35 million
November 20, 2013Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo
AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million. AZ retains …
Horizon Discovery chairman steps down from Board
October 24, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing evans, horizon
Research tools firm Horizon Discovery has confirmed that David Evans has stepped down as chairman of its Board. Dr Ian …
Boehringer in oncology tie-up
January 16, 2013Research and Development, Sales and Marketing Boehringer, Cancer, horizon, x-man
Boehringer Ingelheim has entered a five-year tie-up with a UK biotech company which specialises in helping research into personalised medicines. …
